Although the burden of end-stage heart failure continues to increase, the number of
available organs for heart transplantation (HT) remains inadequate. The HT community has …

The advent of therapies for successful treatment of hepatitis C virus has allowed the heart
and lung transplant community to re-explore the use of hepatitis C virus–positive donors for …

Hepatitis C virus (HCV) infection is a silent killer that leads to rapid progression of liver
cirrhosis and hepatocellular carcinoma (HCC). High prevalence of HCV infection has been …

Nonutilization of organs from consented deceased donors remains a significant factor in
limiting patient access to transplantation. Critical to reducing waste is a clear understanding …

BACKGROUND Lung transplantation offers a survival benefit for patients with end-stage
lung disease. When suitable donors are identified, centers must accept or decline the offer …

Advanced heart failure affects tens of thousands of people in the United States alone with
high morbidity and mortality. Cardiac transplantation offers the best treatment strategy, but …

Background Patients with adult congenital heart disease (ACHD) experience long waitlist
times for heart transplantation (HTx) while a large proportion of donor hearts are refused …

Introduction: Hepatitis C is one of the leading causes of chronic liver disease. The direct-
acting-antivirals has revolutionized the chronic hepatitis C treatment. DAAs can achieve a …

The rising prevalence of congenital heart disease (CHD) among adults has led to increased
heart transplantation (HT) procedures in this population. However, CHD patients face …

A nationwide analysis 1 published in 2017 demonstrated that the US Public Health Service
(PHS)“increased risk” donor (IRD) label—for donors considered to have an increased risk of …